Canature Health Technology Co., Ltd. (SZSE:300272) agreed to acquire additional 12.87% stake in Shanghai Origincell Biological Cryo Equipment Co., Ltd. from Shanghai Senba Investment Center (Limited Partnership) and Shanghai Senlu Investment Center (Limited Partnership) for CNY 270 million on October 10, 2023. As of June 30, 2023, Shanghai Origincell Biological Cryo Equipment Co., Ltd reported total assets of CNY 1.6 billion and net assets of CNY 990 million. The deal has been approved by board of directors and is subject to approval from shareholders of Canature Health Technology Co., Ltd.
Canature Health Technology Co., Ltd.
Equities
300272
CNE1000018L9
Environmental Services & Equipment
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.24 CNY | +0.96% | +2.14% | -15.48% |
1st Jan change | Capi. | |
---|---|---|
-15.48% | 409M | |
+10.59% | 8.7B | |
+29.45% | 2.21B | |
-0.24% | 1.18B | |
+24.85% | 883M | |
-2.50% | 808M | |
-14.90% | 600M | |
+3.40% | 594M | |
-2.33% | 565M | |
-8.50% | 553M |
- Stock Market
- Equities
- 300272 Stock
- News Canature Health Technology Co., Ltd.
- Canature Health Technology Co., Ltd. agreed to acquire additional 12.87% stake in Shanghai Origincell Biological Cryo Equipment Co., Ltd. from Shanghai Senba Investment Center (Limited Partnership) and Shanghai Senlu Investment Center (Limited Partnership) for CNY 270 million.